BF Biosciences maintains positive earnings momentum

April 29, 2025 (MLN): BF Biosciences Limited (PSX: BFBIO) has reported a marginal increase in profitability for the nine months ended March 31, 2025, with net earnings reaching Rs320.3 million, reflecting a 2% year-on-year rise compared to Rs314.1m in the same period last year.

However, earnings per share (EPS) declined to Rs4.08 from Rs4.96, indicating a 17.74% drop, despite stable profit after tax.

The company’s revenue jumped by 44.5% to Rs4.21 billion, up from Rs2.91bn in the corresponding period last year, driven by robust sales performance.

Cost of goods sold also rose sharply by 49.9% to Rs2.48bn, leading to a gross profit of Rs1.74bn, up 37.6% from Rs1.26bn in the prior year.

Administrative expenses grew by 31.4% to Rs42.6m, while selling and distribution expenses surged by nearly 80% to Rs1.08bn, pointing to increased commercial and outreach efforts.

Other expenses stood at Rs58.7mn, up 14.9%, while other income contributed Rs91.9mn—marking a significant increase of 253.7% from Rs26m in the previous year.

Despite a 7.25% rise in finance costs to Rs122.6m, profit before income tax edged up by 8.5% to Rs522.1m from Rs481.2mn a year ago.

The income tax expense climbed by 20.7% to Rs201.8m, limiting the net profit growth over the period.

Copyright Mettis Link News